Clearmind Medicine Licenses Psychedelic Compounds
Ticker: CMND · Form: 6-K · Filed: Apr 17, 2024 · CIK: 1892500
Sentiment: neutral
Topics: licensing-agreement, psychedelics, mental-health, drug-development
TL;DR
Clearmind gets exclusive rights to new psychedelic compounds for mental health treatments.
AI Summary
Clearmind Medicine Inc. announced on April 17, 2024, an exclusive licensing agreement for Generation 3.0 psychedelic compounds. This agreement is for the treatment of mental disorders and involves compounds developed by 03 Life Sciences. The press release is attached to their Form 6-K filing.
Why It Matters
This licensing agreement could advance Clearmind Medicine's pipeline for novel mental disorder treatments, potentially impacting the future of psychedelic-assisted therapy.
Risk Assessment
Risk Level: medium — The company is in the early stages of developing psychedelic compounds, which carry inherent regulatory and clinical trial risks.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- 03 Life Sciences (company) — Licensor of compounds
- April 17, 2024 (date) — Date of press release and announcement
FAQ
What is the specific nature of the Generation 3.0 psychedelic compounds?
The filing does not specify the exact nature of the Generation 3.0 psychedelic compounds, only that they are licensed for the treatment of mental disorders.
What is the duration or financial terms of the exclusive licensing agreement?
The provided text of the 6-K filing does not disclose the specific duration or financial terms of the exclusive licensing agreement.
Which specific mental disorders are targeted by these psychedelic compounds?
The filing states the compounds are for the 'treatment of mental disorders' but does not list specific conditions.
What is the role of 03 Life Sciences in this agreement?
03 Life Sciences is the entity from which Clearmind Medicine Inc. has obtained the exclusive license for the Generation 3.0 psychedelic compounds.
Where is Clearmind Medicine Inc. headquartered?
Clearmind Medicine Inc. is headquartered at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
Filing Stats: 274 words · 1 min read · ~1 pages · Grade level 12.4 · Accepted 2024-04-17 16:00:20
Filing Documents
- ea0204065-6k_clear.htm (6-K) — 11KB
- ea020406502ex99-1_clear.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-033783.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: April 17, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3